CatalystMarker
← board

GLAS

distress 1/10 · well-funded / low risk
$10.500%today-23% from 52w high
glasshousebrands.com357 employeesFounded 2015Long Beach, CADrug Manufacturers - Specialty & Generic
Revenue
$182M
Liquidity
$23M
Runway
Shares 1y

Price & events

+13.8% over 6M
$7.30$10.44$13.58Jan 26Apr 26Jul 261.7Mrating: Lake Street: Buy (2026-07-13)
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
+1.5%
1W
-11.5%
1M
+12.1%
3M
+10.4%
6M
+101.9%
1Y
+47.9%
2Y
+49.8%
5Y
+4.1%
All

Overview

Volume
13.78K
52 Week Range
$5.01 – $13.58
Float Shares
63.89M
% Held by Insiders
8.31%
% Held by Institutions
7.23%
RVOL
0.04x
Beta
0.51

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $16 (+56% upside) · 3 analysts
  • 2026-07-13Lake StreetBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.